Abstract: Objective: To analyze the association of the HLA-Cw6 allele with response to biological agents for the treatment of psoriasis in a Meta analysis. Methods: The relevant studies from MEDLINE, EMBASE, the Cochrane Library, SinoMed, CNKI and Wanfang database from Jan 1, 1974 to Dec 1, 2018 were researched and were analyzed with Meta analysis. Results: Eleven studies were included for analysis. Among these, three kinds of biological agents were contained, including: anti-IL-12/IL-23 antibody Ustekinumab in six studies, anti-TNF-α antagonists in three studies and IL-17/IL-17A receptor antibody Secukinumab in two studies . The analysis of Ustekinumab showed that the score  of PASI decreased by 75% in the patients with HLA-Cw6, which  was higher than that in the patients without HLA-Cw6, with a significant difference (P<0.05). Two Secukinumab and TNF-α antagonist studies showed that there was no significant decrease in PASI score between the patients with and without HLA-Cw6 (P<0.05). Conclusion: HLA-Cw6 positive patients responded better and faster to Ustekinumab than the negative patients. HLA-Cw6 dose not have an impact on the therapeutic efficacy of Secukinumab and TNF-α antagonist. 

Key words: psoriasis, HLA-Cw6, biological agents, Meta-analysis